Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 170

Similar articles for PubMed (Select 24042365)

1.

Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.

Rosenberg SM, Tracy MS, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come SE, Winer EP, Partridge AH.

Ann Intern Med. 2013 Sep 17;159(6):373-81. doi: 10.7326/0003-4819-159-6-201309170-00003.

2.

Summaries for patients. Do women with breast cancer overestimate their risk for cancer in the unaffected breast?

[No authors listed]

Ann Intern Med. 2013 Sep 17;159(6):I-30. doi: 10.7326/0003-4819-159-6-201309170-00001. No abstract available.

PMID:
24042379
3.

Prophylactic mastectomy for the prevention of breast cancer.

Lostumbo L, Carbine N, Wallace J, Ezzo J.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002748. Review. Update in: Cochrane Database Syst Rev. 2010;(11):CD002748.

PMID:
15495033
4.

Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer.

Brewster AM, Parker PA.

Oncologist. 2011;16(7):935-41. doi: 10.1634/theoncologist.2011-0022. Epub 2011 Jun 14. Review.

5.

Prophylactic mastectomy for the prevention of breast cancer.

Lostumbo L, Carbine NE, Wallace J.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD002748. doi: 10.1002/14651858.CD002748.pub3. Review.

PMID:
21069671
6.

Decision-making process of women carrying a BRCA1 or BRCA2 mutation who have chosen prophylactic mastectomy.

McQuirter M, Castiglia LL, Loiselle CG, Wong N.

Oncol Nurs Forum. 2010 May;37(3):313-20. doi: 10.1188/10.ONF.313-320.

PMID:
20439215
7.

Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.

Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Møller P, Weitzel J, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

J Clin Oncol. 2008 Mar 1;26(7):1093-7. doi: 10.1200/JCO.2007.12.6078. Epub 2008 Jan 14.

8.

Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.

Graves KD, Peshkin BN, Halbert CH, DeMarco TA, Isaacs C, Schwartz MD.

Breast Cancer Res Treat. 2007 Sep;104(3):321-9. Epub 2006 Oct 26.

9.

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.

van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, van Asperen CJ, Rutgers EJ, Van't Veer LJ, Tollenaar RA.

Br J Cancer. 2005 Aug 8;93(3):287-92.

10.

Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy.

Yi M, Hunt KK, Arun BK, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F.

Cancer Prev Res (Phila). 2010 Aug;3(8):1026-34. doi: 10.1158/1940-6207.CAPR-09-0130. Epub 2010 Jul 20.

11.

One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).

Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Seynaeve C, van Geel AN, Tilanus MM, Bartels CC, Verhoog LC, Brekelmans CT, Burger CW, Niermeijer MF.

Breast Cancer Res Treat. 2002 May;73(2):97-112.

PMID:
12088120
12.

Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy.

Metcalfe KA, Narod SA.

J Natl Cancer Inst. 2002 Oct 16;94(20):1564-9.

13.

Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.

Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR.

Clin Breast Cancer. 2007 Dec;7(11):875-82. doi: 10.3816/CBC.2007.n.053.

PMID:
18269778
14.

Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.

Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG.

J Clin Oncol. 2003 May 1;21(9):1675-81.

PMID:
12721241
15.

Should the use of contralateral prophylactic mastectomy be increasing as it is?

Wood WC.

Breast. 2009 Oct;18 Suppl 3:S93-5. doi: 10.1016/S0960-9776(09)70282-6.

PMID:
19914552
16.

Contralateral prophylactic mastectomy for patients with unilateral breast cancer.

Tuttle T, Habermann E, Abraham A, Emory T, Virnig B.

Expert Rev Anticancer Ther. 2007 Aug;7(8):1117-22. Review.

PMID:
18028020
17.

Decision making and factors influencing long-term satisfaction with prophylactic mastectomy in women with breast cancer.

Soran A, Ibrahim A, Kanbour M, McGuire K, Balci FL, Polat AK, Thomas C, Bonaventura M, Ahrendt G, Johnson R.

Am J Clin Oncol. 2015 Apr;38(2):179-83. doi: 10.1097/COC.0b013e318292f8a7.

PMID:
23648435
18.

Issues of regret in women with contralateral prophylactic mastectomies.

Montgomery LL, Tran KN, Heelan MC, Van Zee KJ, Massie MJ, Payne DK, Borgen PI.

Ann Surg Oncol. 1999 Sep;6(6):546-52.

PMID:
10493622
19.

Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing.

Tercyak KP, Peshkin BN, Brogan BM, DeMarco T, Pennanen MF, Willey SC, Magnant CM, Rogers S, Isaacs C, Schwartz MD.

J Clin Oncol. 2007 Jan 20;25(3):285-91. Epub 2006 Dec 11.

20.

Perceptions of contralateral breast cancer: an overestimation of risk.

Abbott A, Rueth N, Pappas-Varco S, Kuntz K, Kerr E, Tuttle T.

Ann Surg Oncol. 2011 Oct;18(11):3129-36. doi: 10.1245/s10434-011-1914-x. Epub 2011 Sep 27.

PMID:
21947590
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk